On October 28, 2022, Lineage Cell Therapeutics, Inc. appointed Jill A. Howe as its Chief Financial Officer, effective November 14, 2022. In this capacity, Ms. Howe will serve as the Company's principal financial and accounting officer. Ms. Howe, 46, most recently served as the Chief Financial Officer of DTx Pharma, Inc., a position she held from June 2021 through July 2022.

Prior to joining DTx Pharma, from January 2018 to June 2021, Ms. Howe served as Vice President of Finance and Treasurer for Gossamer Bio, Inc. Prior to Gossamer Bio, she served as Controller & Director of Finance of Amplyx Pharmaceuticals, Inc., from March 2016 to December 2017. She previously held positions, including as Controller and Director of Finance, at Receptos, Inc., and at Somaxon Pharmaceuticals, Inc. Since November 2021, Ms. Howe has served on the board of directors of, and as the chair of the audit committee and as a member of the nominating committee of, Biora Therapeutics, Inc., and since October 2021, has served on the board of directors of Codagenix Inc. Ms. Howe earned a B.S. in Accountancy from San Diego State University.